82 results on '"An, Jingjing"'
Search Results
2. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer
- Author
-
Jiajia Wang, Shudan Wang, Junli Wang, Jingjing Huang, Haishan Lu, Bin Pan, Hanyi Pan, Yanlun Song, Qianqian Deng, Xiaojun Jin, and Guiling Shi
- Subjects
cervical cancer ,cornichon homolog 4 ,immune landscape ,knockdown ,predictive model ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Cornichon homolog 4 (CNIH4) belongs to the CNIH family. It functions as an oncogene in many tumors. However, CNIH4's significance in the immune landscape and its predictive potential in cervical cancer (CESC) is unexplored. Methods CNIH4 levels and its effect on the survival of patients with CESC were evaluated using data retrieved from The Cancer Genome Atlas (TCGA). The oncogenic effect of CNIH4 in CESC was determined using small interfering RNA‐mediated transfected cell lines and tumorigenesis experiments in animal models. Results Higher expression of CNIH4 was found in advanced tumor and pathological stages, as well as lymph node metastasis. CNIH4 expression correlated positively with the infiltration of macrophages M2 and resting dendritic cells into the affected tissue. Additionally, functional enrichment of RNA‐sequencing of CNIH4‐knocked down CESC cell lines showed the association of CNIH4 to the PI3K‐Akt signaling pathway. Single‐sample gene set enrichment analysis highlighted several immune pathways that were elevated in the CESC samples with enhanced levels of CNIH4, including Type‐I and Type‐II IFN‐response pathways. The impact of CNIH4 on drug sensitivity was further assessed using the GDSC database. As CNIH4 is linked to the immune landscape in CESC, this study determined a four‐gene risk prediction signature utilizing CNIH4‐related immunomodulators. The risk score quantified from the prediction signature was an independent predictive indicator in CESC. Receiver operating characteristic curve analysis verified the good predictive ability of the four‐gene signature in TCGA‐CESC cohort. Thus, the CNIH4‐related model showed potential as an auxiliary TNM staging system tool. Conclusion CNIH4 may be an effective predictive biomarker for patients with cervical cancer, thus providing new ideas and research directions for CESC.
- Published
- 2023
- Full Text
- View/download PDF
3. Development of a nutritional screening and assessment indicator system for patients with esophageal cancer in China: Findings from the Delphi method
- Author
-
Jingjing Shang, Wen Dong, Peipei Huang, Yidan Sun, Yuxin He, Hui Li, Shengwu Liao, and Mei Li
- Subjects
Delphi method ,esophageal cancer ,index system ,nutritional assessment ,nutritional screening ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background In China, individuals diagnosed with esophageal cancer are confronted with an elevated risk of nutritional inadequacy or malnutrition throughout the course of their disease, a condition that contributes to various adverse clinical outcomes. A vast corpus of data are burgeoning at an unprecedented rate, primarily due to the revolutionary growth of digitalization technologies and artificial intelligence, notably within the domains of health care and medicine. The purpose of this investigation is to initiate the development of a nutritional screening and assessment indicator framework for patients with esophageal cancer within the Chinese context. We seek to furnish an instrumental reference to facilitate preparations for the forthcoming era of advanced, “deep,” evidence‐based medicine. Methods An integrative methodology was employed to forge the preliminary draft of the nutritional screening and assessment indicator system for preoperative patients with esophageal cancer. This encompassed a rigorous literature survey, in‐depth clinical practice investigation, and the facilitation of expert panel discussions. Thereafter, two iterative consultation phases were conducted using the Delphi method in China. The analytic hierarchy process was deployed to ascertain the weighting of each index within the definitive evaluation indicator system. Results The effective response rates for the dual rounds of expert consultation were 91.7% and 86.4%, with commensurate authority coefficients of 0.97 and 0.91. The Kendall harmony coefficients were ascertained to be 0.19 and 0.14 (p
- Published
- 2023
- Full Text
- View/download PDF
4. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T‐cell lymphoma
- Author
-
Ziyuan Shen, Xicheng Chen, Cai Sun, Tianyi Lu, Yuye Shi, Hao Zhang, Jingjing Ye, Ling Wang, Taigang Zhu, Yuqing Miao, Xudong Zhang, Liang Wang, Guoqi Cai, and Wei Sang
- Subjects
clinicopathologic ,extranodal natural killer/T‐cell lymphoma ,nasal ,nonnasal ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The clinicopathologic characteristics and prognosis of nasal and nonnasal extranodal natural killer T‐cell lymphoma (ENKTL) are considered to be different. However, the underlying features responsible for these differences are not well clarified especially in the era of asparaginase therapy. Methods In total, 1007 newly diagnosed ENKTL patients from 11 medical centers were included in this study. Clinicopathologic characteristics and survival data were collected. The chi‐squared test and Kruskal–Wallis test were utilized for the comparison of different groups. Univariable and multivariable Cox proportional hazards models were used to screen prognostic factors. Results Overall, 869 (86.3%) patients were nasal forms. Compared to patients with nasal ENKTL, nonnasal patients were at more advanced stages and had poor performance status, bone marrow involvement, elevated serum lactate dehydrogenase (LDH), and CD56‐negative status (p
- Published
- 2023
- Full Text
- View/download PDF
5. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies
- Author
-
Gang Yang, Jingjing Huang, Ji Sun, and Li Wang
- Subjects
chemotherapy ,elderly ,IMRT ,nasopharyngeal carcinoma ,survival outcomes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background With the coming of the aging society, the incidence of elderly nasopharyngeal carcinoma (NPC) has been increasing which may result in considerable disease burden; however, the optimal treatment strategy for elderly patients is still debatable. Methods and Results Clinical data on 294 elderly NPC patients aged ≥70 treated between 2009 and 2019 was analyzed. Kaplan–Meier method was used to estimate overall survival (OS) and cancer‐specific survival (CSS) rates. With a median follow‐up of 53.25 months, the 5‐year estimated OS and CSS for the entire group were 59.5% and 69.8%, respectively. 146 patients died within the follow‐up period, of which recurrence + metastasis (48%) and internal medical disease unrelated to NPC (32%) are the primary causes of death. On univariable analysis, (IMRT vs. 3D‐CRT) (p = 0.001; p = 0.000), T stage (p = 0.001; p = 0.000), N stage (p = 0.013; p = 0.000) and clinical stage (p = 0.000; p = 0.000) were associated with OS and CSS; Charlson Comorbidity Index (CCI) (p = 0.016) was associated with OS. The addition of chemotherapy (CT) correlated with better CSS (p = 0.039), but did not improve OS (p = 0.056) for stage III–IV subgroup. On multivariate analysis, advanced clinical stage independently predicted poorer OS (p = 0.002) and CSS (p = 0.000). In addition, the application of IMRT was an independent protective factor on both OS (p = 0.028) and CSS (p = 0.030). Conclusion IMRT is a reasonable treatment strategy to improve survival for elderly NPC patients aged over 70 years; consideration of adding chemotherapy for elderly population should be weighed carefully.
- Published
- 2023
- Full Text
- View/download PDF
6. Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia
- Author
-
Yuyan Wu, Mingying Li, Guangqiang Meng, Yuechan Ma, Jingjing Ye, Tao Sun, and Chunyan Ji
- Subjects
acute myeloid leukemia ,immune checkpoint ,PD1 ,prognosis ,single nucleotide polymorphism ,susceptibility ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Chemotherapy is still the standard regimen for treating acute myeloid leukemia (AML) and its disappointing efficacy requires the urgent need for new therapeutic targets. It is well known that immune response plays an increasingly significant role in the pathogenesis of AML. Methods We detected nine single nucleotide polymorphisms (SNPs) in immune checkpoint‐related genes, including PD1, LAG3, TIM3, and TIGIT in 285 AML inpatients and 324 healthy controls. SNP genotyping was performed on the MassARRAY platform. Furthermore, we analyzed the relationship between the susceptibility and prognosis of AML and the selected SNPs. Results Our results showed that rs2227982 and rs10204525 in PD1 were significantly associated with susceptibility to AML after false discovery rate correction. PD1 rs10204525 also showed a significant correlation with the response to chemotherapy and risk stratification of AML. Importantly, the AA genotype of PD1 (rs2227982) under the recessive model showed a negative impact on AML prognosis independently. Conclusions Our results indicate that PD1 SNPs are important for susceptibility and prognosis in AML, which may provide a new therapeutic target for AML patients.
- Published
- 2023
- Full Text
- View/download PDF
7. Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma
- Author
-
Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, and Hui Liu
- Subjects
diffuse large B‐cell lymphoma ,early mortality ,geriatric assessment ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Geriatric assessment can aid in optimizing treatment strategies and supportive interventions for older patients with diffuse large B‐cell lymphoma (DLBCL). Fondazione Italiana Linformi has recently introduced novel geriatric assessment tools, simplified Geriatric Assessment (sGA) and Elderly Prognostic Index (EPI), aimed at tailoring the treatment and predicting the outcomes for older patients with DLBCL. The objectives of this study are the validation and possible modification of the sGA and EPI in China. In the study, both sGA and EPI demonstrated the predictive capabilities for overall survival (OS) and early mortality (both p
- Published
- 2024
- Full Text
- View/download PDF
8. Health insurance as a moderator in the relationship between financial toxicity and medical cost‐coping behaviors: Evidence from patients with lung cancer in China
- Author
-
Yongchun Cui, Jingjing Lv, Xiaoyu Hu, and Dawei Zhu
- Subjects
China ,financial toxicity ,health insurance ,medical cost‐coping behaviors ,patients with lung cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective This study investigates the relationship between financial toxicity and medical cost‐coping behaviors (MCCB) in Chinese patients with lung cancer, with a particular focus on the moderating role of health insurance. Methods We surveyed 218 patients with lung cancer and assessed their Comprehensive Score for Financial Toxicity (COST) and self‐reported MCCB. Patients were categorized into Urban Employee's Basic Medical Insurance (UEBMI) group and Urban–Rural Resident Basic Medical Insurance Scheme (URRBMI) groups by their medical insurance, and matched for socioeconomic, demographic, and disease characteristics via propensity score. Results Significant different characteristics were noted between UEBMI patients and URRBMI patients. Patients with UEBMI had higher COST scores but lower levels of MCCB compared to URRBMI patients in the original dataset. After data matching, multivariate logit regression analysis showed that better financial toxicity was associated with lower levels of MCCB (OR = 0.95, 95% CI: 0.92–0.99). Health insurance type did not have a direct association with cost‐coping behaviors, but an interaction was observed between health insurance type and financial toxicity. Among patients with URRBMI, better financial toxicity was associated with lower levels of cost‐coping behaviors (OR = 0.89, 95% CI: 0.83–0.95). Patients with UEBMI had a lower probability of engaging in any cost‐coping behaviors in situations of worse financial toxicity compared to patients with URRBMI. Conclusion The findings suggest that financial toxicity is correlated with MCCB in Chinese patients with lung cancer. The type of health insurance, specifically UEBMI and URRBMI, plays a moderating role in this relationship. Understanding these dynamics is essential for developing targeted interventions and policies to mitigate financial toxicity and improve patients' management of medical costs.
- Published
- 2024
- Full Text
- View/download PDF
9. Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort
- Author
-
Lei Wang, Jingjing Ge, Liwen Feng, Zehua Wang, Wenjia Wang, Huiqiong Han, and Yanru Qin
- Subjects
gastric cardia adenocarcinoma ,LODDS ,nomogram ,prognosis ,SEER database ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Gastric cardia adenocarcinoma (GCA) is a highly fatal form of cancer in humans. The aim of this study was to extract clinicopathological data of postoperative patients with GCA from the Surveillance, Epidemiology, and End Results database, analyze prognostic risk factors, and build a nomogram. Methods In this study, the clinical information of 1448 patients with GCA who underwent radical surgery and were diagnosed between 2010 and 2015 was extracted from the SEER database. The patients were then randomly divided into training (n = 1013) and internal validation (n = 435) cohorts at a 7:3 ratio. The study also included an external validation cohort (n = 218) from a Chinese hospital. The study used the Cox and LASSO models to pinpoint the independent risk factors linked to GCA. The prognostic model was constructed according to the results of the multivariate regression analysis. To assess the predictive accuracy of the nomogram, four methods were used: C‐index, calibration curve, time‐dependent ROC curve, and DCA curve. Kaplan–Meier survival curves were also generated to illustrate the differences in cancer‐specific survival (CSS) between the groups. Results The results of the multivariate Cox regression analysis showed that age, grade, race, marital status, T stage, and log odds of positive lymph nodes (LODDS) were independently associated with cancer‐specific survival in the training cohort. Both the C‐index and AUC values depicted in the nomogram were greater than 0.71. The calibration curve revealed that the nomogram's CSS prediction was consistent with the actual outcomes. The decision curve analysis suggested moderately positive net benefits. Based on the nomogram risk score, significant differences in survival between the high‐ and low‐risk groups were observed. Conclusions Race, age, marital status, differentiation grade, T stage, and LODDS are independent predictors of CSS in patients with GCA after radical surgery. Our predictive nomogram constructed based on these variables demonstrated good predictive ability.
- Published
- 2023
- Full Text
- View/download PDF
10. It is not the time to abandon intraoperative frozen section in endometrioid adenocarcinoma: A large‐scale, multi‐center, and retrospective study
- Author
-
Xiaohang Yang, Jingjing Yin, Yu Fu, Yuanming Shen, Chuyao Zhang, Shuzhong Yao, Congjian Xu, Min Xia, Ge Lou, Jihong Liu, Bei Lin, Jianliu Wang, Weidong Zhao, Jieqing Zhang, Wenjun Cheng, Hongyan Guo, Ruixia Guo, Fengxia Xue, Xipeng Wang, Lili Han, Xiaomao Li, Ping Zhang, Jianguo Zhao, Wenting Li, Yingyu Dou, Zizhuo Wang, Jingbo Liu, Kezhen Li, Gang Chen, Chaoyang Sun, Beibei Wang, and Xingsheng Yang
- Subjects
endometrioid adenocarcinoma ,high‐grade ,intraoperative frozen section ,myometrial invasion ,retrospective studies ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction Stage IB (deep myometrial invasion) high‐grade endometrioid adenocarcinoma (EA), regardless of LVSI status, is classified into high‐intermediate risk groups, requiring surgical lymph node staging. Intraoperative frozen section (IFS) is commonly used, but its adequacy and reliability vary between reports. Hence, we determined the utility of IFS in identification of high‐risk factors, including deep myometrial invasion and high‐grade. Method We retrospectively analyzed 9,985 cases operated with hysterectomy and diagnosed with FIGO stage I/II EA in postoperative paraffin section (PS) results at 30 Chinese hospitals from 2000 to 2019. We determined diagnostic performance of IFS and investigated whether the addition of IFS to preoperative biopsy and imaging could improve identification of high‐risk factors. Results IFS and postoperative PS presented the highest concordance in assessing deep myometrial invasion (Kappa: 0.834), followed by intraoperative gross examination (IGE Kappa: 0.643), MRI (Kappa: 0.395), and CT (Kappa: 0.207). IFS and postoperative PS presented the highest concordance for high‐grade EA (Kappa: 0.585) compared to diagnostic curettage (D&C 0.226) and hysteroscope (Hys 0.180). Sensitivity and specificity for detecting deep myometrial invasion were 86.21 and 97.20% for IFS versus 51.72 and 88.81% for MRI, 68.97 and 94.41% for IGE. These figures for detecting high‐grade EA were 58.21 and 96.50% for IFS versus 16.42 and 98.83% for D&C, 13.43 and 98.64% for Hys. Parallel strategies, including MRI‐IFS (Kappa: 0.626), D&C‐IFS (Kappa: 0.595), and Hys‐IFS (Kappa: 0.578) improved the diagnostic efficiencies of individual preoperative examinations. Based on the high sensitivity of IFS, parallel strategies improved the sensitivities of preoperative examinations to 89.66% (MRI), 64.18% (D&C), 62.69% (Hys), respectively, and these differences were statistically significant (p = 0.000). Conclusion IFS presented reasonable agreement rates predicting postoperative PS results, including deep myometrial invasion and high‐grade. IFS helps identify high‐intermediate risk patients in preoperative biopsy and MRI and guides intraoperative lymphadenectomy decisions in EA.
- Published
- 2023
- Full Text
- View/download PDF
11. ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women
- Author
-
Chao Wang, Jingjing Zhou, Lili Wang, Tongyu Xing, Hongji Dai, Yao Zhou, Lisha Qi, Yanrui Zhao, Caiyun Huang, Ding Li, Haixin Li, Mulin Jun Li, Ben Liu, Hong Zheng, Kexin Chen, and Lian Li
- Subjects
ABH antigens ,ABO blood group ,epithelial ovarian cancer ,risk ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background ABO blood groups has been associated with risk of several cancers; however, the results for an association with ovarian cancer are inconsistent and little is known about the expression of histo‐blood group (ABH) antigens and ABO gene in ovarian tumor tissues. Methods To assess the impact of genotype‐derived ABO blood types on the risk of EOC, we conducted a case–control study in 1,870 EOC and 4,829 controls. Expression of A and B antigen in 70 pairs of ovarian tumor tissues and adjacent normal tissues were detected by immunohistochemistry. Gene expression and DNA methylation profiling was conducted in ovarian tumor tissues. Results We identified that blood group A was associated with increased risk for EOC compared to blood group O (OR = 1.18, 95% CI = 1.03–1.36, p = 0.019). Increased frequency of aberrant expression of histo‐blood group antigens was observed in patients with blood group A (76.5%) compared to patients with blood group O (21.1%) and B (5.0%) by immunohistochemistry (p
- Published
- 2023
- Full Text
- View/download PDF
12. Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016)
- Author
-
Xu, Peng, primary, Luo, Wen, additional, Hu, Jingjing, additional, Ma, Xiaobin, additional, Hao, Qian, additional, Hui, Wentao, additional, Zhou, Zhangjian, additional, Lin, Shuai, additional, Wang, Meng, additional, Wu, Hao, additional, Dai, Zhijun, additional, and Kang, Huafeng, additional
- Published
- 2024
- Full Text
- View/download PDF
13. The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
- Author
-
Hanxiao Chen, Dingzhi Huang, Gen Lin, Xue Yang, Minglei Zhuo, Yujia Chi, Xiaoyu Zhai, Bo Jia, Jingjing Wang, Yuyan Wang, Jianjie Li, Tongtong An, Meina Wu, Ziping Wang, and Jun Zhao
- Subjects
efficacy ,KRAS mutation ,NSCLC ,prevalence ,treatme ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective Kirsten rat sarcoma viral oncogene homolog (KRAS) is an important driver gene of non‐small cell lung cancer (NSCLC). Despite a rapid progress achieved in the targeted therapy, chemotherapy remains the standard treatment option for patients with KRAS‐mutant NSCLC. This study aimed to assess real‐world data of Chinese patients with KRAS‐mutant NSCLC undergoing chemotherapy and/or immunotherapy. Methods KRAS mutational status was analyzed using next‐generation sequencing of 150,327 NSCLC patients from the Lung Cancer Big Data Precise Treatment Collaboration Group (LANDSCAPE) project (Cohort I). Treatment data were collected and analyzed retrospectively from 4348 NSCLC patients who were admitted to the Peking University Cancer Hospital and Institute between January 2009 and October 2020 (Cohort II). Results In Cohort I, 18,224 patients were detected with KRAS mutations (12.1%) of whom G12C (29.6%) was the most frequent subtype, followed by G12D (18.1%) and G12V (17.5%). In case of concomitant mutations, TP53 had the highest incidence of 33.6%, followed by EGFR (11.6%), STK11 (10.4%), KEAP1(6.2%), and CDKN2A (6.0%). Cohort II included 497 patients (11.4%) with KRAS mutations. In the first‐line chemotherapeutic analysis of Cohort II, patients benefited more from the pemetrexed/platinum (PP) regimen than the gemcitabine/platinum (GP) or taxanes/platinum (TP) regimen (median progression‐free survival [PFS], 6.4 vs. 4.9 vs. 5.6 months, hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.48–0.88, p = 0.033 and HR = 0.69, 95% CI 0.47–1.00, p = 0.05, respectively), with no significant difference when combined with bevacizumab. Regarding patients who received immune checkpoint inhibitors (ICIs), the objective response rate was 26% for a median PFS of 9.6 months (95% CI 6.16–13.03). Patients who received ICIs combined with chemotherapy had a significantly longer survival than monotherapy (median PFS, 13.9 vs. 5.2 months, HR = 0.59, 95% CI 0.35–0.99, p = 0.049). Conclusion KRAS is an important driver gene in NSCLC, compromising 12.1% in this study, and G12C was noted as the most common subtype. Patients with KRAS‐mutant NSCLC could benefit from pemetrexed‐based chemotherapy and ICIs.
- Published
- 2022
- Full Text
- View/download PDF
14. Identification of a novel six‐gene signature with potential prognostic and therapeutic value in cervical cancer
- Author
-
Xinyu Qu, Zhiwen Shi, Jingjing Guo, Chenyan Guo, Junjun Qiu, and Keqin Hua
- Subjects
cervical cancer ,gene signature ,prognosis ,tumour immune microenvironment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction Cervical cancer has high mortality, high recurrence and poor prognosis. Although prognostic biomarkers such as clinicopathological features have been proposed, their accuracy and precision are far from satisfactory. Therefore, novel biomarkers are urgently needed for disease surveillance, prognosis prediction and treatment selection. Materials Differentially expressed genes (DEGs) between cervical cancer and normal tissues from three microarray datasets extracted from the Gene Expression Omnibus platform were identified and screened. Based on these DEGs, a six‐gene prognostic signature was constructed using cervical squamous cell carcinoma and endocervical adenocarcinoma data from The Cancer Genome Atlas. Next, the molecular functions and related pathways of the six genes were investigated through gene set enrichment analysis and co‐expression analysis. Additionally, immunophenoscore analysis and the QuartataWeb Server were employed to explore the therapeutic value of the six‐gene signature. Results We discovered 178 overlapping DEGs in three microarray datasets and established a six‐gene (APOC1, GLTP, ISG20, SPP1, SLC24A3 and UPP1) prognostic signature with stable and excellent performance in predicting overall survival in different subgroups. Intriguingly, the six‐gene signature was closely associated with the immune response and tumour immune microenvironment. The six‐gene signature might be used for predicting response to immune checkpoint inhibitors (ICIs) and the six genes may serve as new drug targets for cervical cancer. Conclusion Our study established a novel six‐gene (APOC1, GLTP, ISG20, SPP1, SLC24A3 and UPP1) signature that was closely associated with the immune response and tumour immune microenvironment. The six‐gene signature was indicative of aggressive features of cervical cancer and therefore might serve as a promising biomarker for predicting not only overall survival but also ICI treatment effectiveness. Moreover, three genes (UPP1, ISG20 and GLTP) within the six‐gene signature have the potential to become novel drug targets.
- Published
- 2021
- Full Text
- View/download PDF
15. ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation
- Author
-
Jianjun Tang, Chuang Zhang, Jingjing Lin, Peng Duan, Jian Long, and Hongyan Zhu
- Subjects
5‐HETE ,Alox5 ,chemotherapy ,gastric cancer ,MEK/ERK ,zileuton ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Recent studies highlight the regulatory role of arachidonate lipoxygenase5 (Alox5) and its metabolite 5‐hydroxyeicosatetraenoic acid (5‐HETE) in cancer tumorigenesis and progression. In this study, we analyzed the expression, biological function and the downstream signaling of Alox5 in gastric cancer. Methods Alox5 protein levels were measured using IHC and ELISA. Growth, migration and survival assays were performed. Phosphorylation of molecules involved in growth and survival signaling were analyzed by WB. Analysis of variance and t‐test were used for statistic analysis. Results Alox5 and 5‐HETE levels were upregulated in gastric cancer patients. ALOX5 overexpression or 5‐HETE addition activates gastric cancer cells and reduces chemotherapy’s efficacy. In contrast, ALOX5 inhibition via genetic and pharmacological approaches suppresses gastric cancer cells and enhances chemotherapy’s efficacy. In addition, Alox5 inhibition led to suppression of ERK‐mediated signaling pathways whereas ALOX5‐5‐HETE activates ERK‐mediated signaling in gastric cancer cells. Conclusions Our work demonstrates the critical role of ALOX5‐5‐HETE in gastric cancer and provides pre‐clinical evidence to initialize clinical trial using zileuton in combination with chemotherapy for treating gastric cancer.
- Published
- 2021
- Full Text
- View/download PDF
16. Health insurance as a moderator in the relationship between financial toxicity and medical cost‐coping behaviors: Evidence from patients with lung cancer in China
- Author
-
Cui, Yongchun, primary, Lv, Jingjing, additional, Hu, Xiaoyu, additional, and Zhu, Dawei, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma
- Author
-
Yun, Xiaoya, primary, Bai, Jiefei, additional, Feng, Ru, additional, Li, Jiangtao, additional, Wang, Ting, additional, Yang, Yazi, additional, Yin, Jingjing, additional, Qian, Long, additional, Zhang, Shuai, additional, Cao, Qingyun, additional, Xue, Xiaoxuan, additional, Jing, Hongmei, additional, and Liu, Hui, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer
- Author
-
Wang, Jiajia, primary, Wang, Shudan, additional, Wang, Junli, additional, Huang, Jingjing, additional, Lu, Haishan, additional, Pan, Bin, additional, Pan, Hanyi, additional, Song, Yanlun, additional, Deng, Qianqian, additional, Jin, Xiaojun, additional, and Shi, Guiling, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Development of a nutritional screening and assessment indicator system for patients with esophageal cancer in China: Findings from the Delphi method
- Author
-
Shang, Jingjing, primary, Dong, Wen, additional, Huang, Peipei, additional, Sun, Yidan, additional, He, Yuxin, additional, Li, Hui, additional, Liao, Shengwu, additional, and Li, Mei, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
- Author
-
Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Huirong Chang, Xiaming Zhu, Lei Yu, Depei Wu, and Chengcheng Fu
- Subjects
chimeric antigen receptor T (CAR T) cell ,dose‐escalation ,efficacy ,multiple myeloma ,relapsed and/or refractory ,safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell maturation antigen (BCMA)‐CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patients, among whom 7 received autologous infusion and 3 received allogeneic infusion. The median follow‐up time was 20 months. The most common grade 3/4 treatment‐emergent toxicities were hematological toxicities. Cytokine‐release syndrome (CRS) adverse reactions were grade 1/2 in 9 out of 10 subjects. No dose‐limited toxicity (DLT) was observed for BCMA‐CAR‐positive T cells ≤5 × 107/kg), while two patients with dose‐levels of 5–6.5 × 107/kg experienced DLTs. The overall response rate was 90% (five partial responses and four stringent complete responses). Three out of four patients with stringent complete responses to autologous CART had progression‐free survival for over 2 years. The three patients with allogeneic CART experienced disease progression within 2 months. These results evidence the sequential infusion's preliminarily tolerability and efficacy in RRMM, and present a simple and safe design applicable for the establishment of multiple CART therapy.
- Published
- 2021
- Full Text
- View/download PDF
21. Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR‐206 to upregulate NETO2 and FOXP1 expression
- Author
-
Chunyu Zhang, Yan Luo, Jingjing Cao, Xiaoyu Wang, Zhiwei Miao, and Guoqing Shao
- Subjects
angiogenesis ,esophageal squamous cell carcinoma ,exosomal ,FAM225A ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Esophageal cancer is one of the leading causes of cancer‐related deaths worldwide. FAM225A is a novel lncRNA, only has been explored in nasopharyngeal carcinoma tumorigenesis. This study aims to investigate the regulatory mechanism of FAM225A in esophageal squamous cell carcinoma (ESCC). We discovered that FAM225A exhibited higher expression in ESCC. The silence of FAM225A attenuated cell viability, migration, and invasion, but facilitated cell apoptosis in ESCC. Exosome‐mediated transfer of lncRNA FAM225A could participate in ESCC progression. In addition, we found that miR‐206 bound to FAM225A. Moreover, we further demonstrated that FAM225A absorbed miR‐206 to upregulate NETO2 and FOXP1 expression, and FOXP1 acted as a transcription factor to enhance FAM225A expression. Eventually, it was revealed that the overexpression of NETO2 or FOXP1 rescued the effects of FAM225A repression on ESCC progression. Our results suggested that FAM225A upregulated NETO2 and FOXP1 expression by sponging miR‐206 to accelerate ESCC progression and angiogenesis. These results determined the biological role of lncRNA FAM225A in ESCC tumorigenesis, and FAM225A may be a promising biomarker for ESCC treatment.
- Published
- 2020
- Full Text
- View/download PDF
22. Effect of the surgical approach on survival outcomes in patients undergoing radical hysterectomy for cervical cancer: A real‐world multicenter study of a large Chinese cohort from 2006 to 2017
- Author
-
Chenyan Guo, Xiaoyan Tang, Yan Meng, Ying Zhang, Xuyin Zhang, Jingjing Guo, Xiaohong Lei, Junjun Qiu, and Keqin Hua
- Subjects
cervical cancer ,laparotomy ,matching ,minimally invasive surgery ,radical hysterectomy ,survival outcome ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective To compare survival outcomes of minimally invasive surgery (MIS) and laparotomy in early‐stage cervical cancer (CC) patients. Methods A multicenter retrospective cohort study was conducted with International Federation of Gynecology and Obstetrics (FIGO, 2009) stage IA1 (lymphovascular invasion)‐IIA1 CC patients undergoing MIS or laparotomy at four tertiary hospitals from 2006 to 2017. Propensity score matching and weighting and multivariate Cox regression analyses were performed. Survival was compared in various matched cohorts and subgroups. Results Three thousand two hundred and fifty‐two patients (2439 MIS and 813 laparotomy) were included after matching. (1) The 2‐ and 5‐year recurrence‐free survival (RFS) (2‐year, hazard ratio [HR], 1.81;95% confidence interval [CI], 1.09‐3.0; 5‐year, HR, 2.17; 95% CI, 1.21‐3.89) or overall survival (OS) (2‐year, HR, 1.87; 95% CI, 1.03‐3.40; 5‐year, HR, 2.57; 95% CI, 1.29‐5.10) were significantly worse for MIS in patients with stage I B1, but not the cohort overall (2‐year RFS, HR, 1.04; 95% CI, 0.76‐1.42; 2‐year OS, HR, 0.99; 95% CI, 0.70‐1.41; 5‐year RFS, HR, 1.12; 95% CI, 0.76‐1.65; 5‐year OS, HR, 1.20; 95% CI, 0.79‐1.83) or other stages (2) In a subgroup analysis, MIS exhibited poorer survival in many population subsets, even in patients with less risk factors, such as patients with squamous cell carcinoma, negative for parametrial involvement, with negative surgical margins, negative for lymph node metastasis, and deep stromal invasion
- Published
- 2020
- Full Text
- View/download PDF
23. Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
- Author
-
Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng, and Kailin Xu
- Subjects
CAR‐T ,CD19 ,CD20 ,clinical trial ,DLBCL ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Methods Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti‐CD19 and anti‐CD20 CAR‐T cells. Treatment response, toxicity, and persistence were monitored continuously. Results Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%‐94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%‐74.3%) had a complete response (CR). Peak levels of anti‐CD19 and anti‐CD20 CAR cells were associated with response (P = .007 and .002). Grade 3‐4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression‐free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. Conclusions Coadministration of anti‐CD19 and CD20 CAR‐T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178.
- Published
- 2020
- Full Text
- View/download PDF
24. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T‐cell lymphoma
- Author
-
Shen, Ziyuan, primary, Chen, Xicheng, additional, Sun, Cai, additional, Lu, Tianyi, additional, Shi, Yuye, additional, Zhang, Hao, additional, Ye, Jingjing, additional, Wang, Ling, additional, Zhu, Taigang, additional, Miao, Yuqing, additional, Zhang, Xudong, additional, Wang, Liang, additional, Cai, Guoqi, additional, and Sang, Wei, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies
- Author
-
Yang, Gang, primary, Huang, Jingjing, additional, Sun, Ji, additional, and Wang, Li, additional
- Published
- 2023
- Full Text
- View/download PDF
26. Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia
- Author
-
Wu, Yuyan, primary, Li, Mingying, additional, Meng, Guangqiang, additional, Ma, Yuechan, additional, Ye, Jingjing, additional, Sun, Tao, additional, and Ji, Chunyan, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia
- Author
-
Yanxin Chen, Peifang Jiang, Jingjing Wen, Zhengjun Wu, Jiazheng Li, Yuwen Chen, Lingyan Wang, Donghui Gan, Yingyu Chen, Ting Yang, Minhui Lin, and Jianda Hu
- Subjects
acute lymphoblastic leukemia ,bioinformatic analysis ,glucocorticoid resistance ,MYC ,signaling pathway ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Glucocorticoids (GC) are the foundation of the chemotherapy regimen in acute lymphoblastic leukemia (ALL). However, resistance to GC is observed more frequently than resistance to other chemotherapy agents in patients with ALL relapse. Moreover, the mechanism underlying the development of GC resistance in ALL has not yet been fully uncovered. In this study, we used bioinformatic analysis methods to integrate the candidate genes and pathways participating in GC resistance in ALL and subsequently verified the bioinformatics findings with in vitro cell experiments. Ninety‐nine significant common differentially expressed genes (DEGs) associated with GC resistance were determined by integrating two gene profile datasets, including GC‐sensitive and ‐resistant samples. Using Kyoto Encyclopedia of Genes and Genomes (KEGG) and REACTOME pathways analysis, the signaling pathways in which DEGs were significantly enriched were clustered. The GC resistance‐related biologically functional interactions were visualized as DEG‐associated Protein–Protein Interaction (PPI) network complexes, with 98 nodes and 127 edges. MYC, a node which displayed the highest connectivity in all edges, was highlighted as the core gene in the PPI network. Increased C‐MYC expression was observed in adriamycin‐resistant BALL‐1/ADR cells, which we demonstrated was also resistant to dexamethasone. These results outlined a panorama in which the solitary and scattered experimental results were integrated and expanded. The potential promising target of the candidate pathways and genes involved in GC resistance of ALL was concomitantly revealed.
- Published
- 2020
- Full Text
- View/download PDF
28. MicroRNA‐124: An emerging therapeutic target in cancer
- Author
-
Xinqi Jia, Xu Wang, Xiaorong Guo, Jingjing Ji, Ge Lou, Junjie Zhao, Wenjia Zhou, Mian Guo, Maomao Zhang, Chao Li, Sheng Tai, and Shan Yu
- Subjects
cancer ,miR‐124 ,miRNAs ,oncotherapy target ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract MicroRNAs (miRNAs) are noncoding single‐stranded RNAs, approximately 20‐24 nucleotides in length, known as powerful posttranscriptional regulators. miRNAs play important regulatory roles in cellular processes by changing messenger RNA expression and are widely involved in human diseases, including tumors. It has been reported in the literature that miRNAs have a precise role in cell proliferation, programmed cell death, differentiation, and expression of coding genes. MicroRNA‐124 (miR‐124) has reduced exparession in various human neoplasms and is believed to be related to the occurrence, development, and prognosis of malignant tumors. In our review, we focus on the specific molecular functions of miR‐124 and the downstream gene targets in major cancers, which provide preclinical evidence for the treatment of human cancer. Although some obstacles exist, miR‐124 is still attracting intensive research focus as a promising and effective anticancer weapon.
- Published
- 2019
- Full Text
- View/download PDF
29. Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway
- Author
-
Liwei Wu, Jingjing Li, Tong Liu, Sainan Li, Jiao Feng, Qiang Yu, Jie Zhang, Jiaojiao Chen, Yuting Zhou, Jie Ji, Kan Chen, Yuqing Mao, Fan Wang, Weiqi Dai, Xiaoming Fan, Jianye Wu, and Chuanyong Guo
- Subjects
apoptosis ,autophagy ,hepatocellular carcinoma ,JAK2/STAT3 pathway ,metastasis ,quercetin ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective Hepatocellular carcinima is one of the most common tumors in clinic and also one of the leading causes of death from cancer worldwide. Quercetin shows significant effects on blocking the development of various cancers. Methods We used the human hepatocellular carcinoma LM3 and nude mice tumor model to assess the effects of quercetin in hepatocellular carcinoma and clarify its mechanism of action. We collected LM3 cell line treated with different doses of quercetin at different time periods and determined the vital indexes. The liver tissues of mice were collected and used for western boltting (WB), Hematoxylin and Eosin (H&E) and TUNEL staining. Results Results indicated that quercetin suppressed the Hepatocellular carcinoma (HCC) growth both in vivo and in vitro. Quercetin could disturb LM3 cells proliferation and cell cycle distribution, thus inducing apoptosis. At the same time, quercetin inhibited LM3 cells migration and invasion and promoted HCC autophagy. These effects at least partly depended on the down‐regulation of the activation of JAK2 and STAT3 by quercetin. Conclusion Quercetin inhibited hepatocellular carcinoma progression by modulating cell apoptosis, migration, invasion, and autophagy; and its effects were at least partly related with the JAK2/STAT3 signaling pathway.
- Published
- 2019
- Full Text
- View/download PDF
30. Improved characterization of the relationship between long intergenic non‐coding RNA Linc00152 and the occurrence and development of malignancies
- Author
-
Jiasheng Xu, Jingjing Guo, Yangkai Jiang, Yujun Liu, Kaili Liao, Zhonghua Fu, and Zhenfang Xiong
- Subjects
linc00152 ,long non‐coding RNA ,malignant tumor ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Linc00152, located on chromosome 2p11.2, is a long intergenic non‐coding RNA molecule with 828 nucleotides that is highly expressed in many types of human tumor tissues, especially in malignant tumors of the digestive system. Linc00152 promotes the occurrence and development of tumors by increasing tumor cell proliferation, invasion, metastasis, and apoptosis. Additionally, linc00152 contributes to the carcinogenesis of several cancers, including gastric cancer, liver cancer, hepatocellular carcinoma, gallbladder cancer, clear cell renal cell carcinoma, and colorectal cancer, by disturbing various signaling pathways (eg PI3K/AKT, mTOR, IL‐1, and NOTCH 1 signaling pathways). High linc00152 expression levels are associated with chemoresistance as well as poor prognosis and shorter survival. Continual advances made in the relevant research have indicated that linc00152 may be useful as a new tumor molecular biomarker, applicable for tumor diagnosis, targeted therapy, and prognosis assessment. This review summarizes the progress in the research into the relationship between linc00152 and the occurrence and development of malignancies based on molecular functions, regulatory mechanisms, and clinical applications.
- Published
- 2019
- Full Text
- View/download PDF
31. Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort
- Author
-
Wang, Lei, primary, Ge, Jingjing, additional, Feng, Liwen, additional, Wang, Zehua, additional, Wang, Wenjia, additional, Han, Huiqiong, additional, and Qin, Yanru, additional
- Published
- 2023
- Full Text
- View/download PDF
32. Retracted: Interference of the long noncoding RNA CDKN2B‐AS1 upregulates miR‐181a‐5p/TGFβI axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells
- Author
-
Lihong Zhu, Quanhua Zhang, Shaoping Li, Shan Jiang, Jingjing Cui, and Ge Dang
- Subjects
CDKN2B‐AS1 ,cervical cancer ,epithelial‐mesenchymal transition ,senescence ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Long noncoding RNA (lncRNA) CDKN2B‐AS1 has been shown to play a crucial role in the development as well as in the prognosis of various human cancers, including cervical cancer. However, the underlying mechanisms need to be further explored between CDKN2B‐AS1 and cervical cancer. In the present study, RT‐PCR showed that the mRNA level of CDKN2B‐AS1 was significantly upregulated while the miR‐181a‐5p was downregulated in cervical cancer cell lines. In addition, the interference of CDKN2B‐AS1 by shRNA resulted in the suppression of cell proliferation, invasion, migration and promotion of apoptosis and senescence, and either CDKN2B‐AS1 overexpression or miR‐181a‐5p showed reversed results. Further studies demonstrated that CDKN2B‐AS1 could directly interact with miR‐181a‐5p, and that there was an inverse correlation between miR‐181a‐5p and CDKN2B‐AS1. In addition, we found that TGFβI was a target of miR‐181a‐5p and could be downregulated by CDKN2B‐AS1 knockdown. Moreover, the in vivo experiments further demonstrated the contribution of CDKN2B‐AS1 in cervical cancer including tumor growth, apoptosis inhibition and senescence inhibition, and CDKN2B‐AS1 knockdown could inhibit the aforementioned activities. In summary, our study demonstrated that the CDKN2B‐AS1/miR‐181a‐5p/TGFβI axis might play a vital role in cervical cancer development.
- Published
- 2019
- Full Text
- View/download PDF
33. Overexpression of long non‐coding RNA NORAD promotes invasion and migration in malignant melanoma via regulating the MIR‐205‐EGLN2 pathway
- Author
-
Yong Chen, Ke Cao, Jingjing Li, Aijun Wang, Lichun Sun, Jintian Tang, Wei Xiong, Xiao Zhou, Xiang Chen, Jianda Zhou, and Yan Liu
- Subjects
long non‐coding RNA ,melanoma ,microRNA ,oncogene ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Growing evidence suggests that long non‐coding RNAs NORAD and miR‐205 play a significant role in regulating cancer progression and metastasis. In this study, high expression of NORAD was firstly observed in melanoma tissues and human malignant melanoma cell lines, our aim was to study the interaction of them in the process of invasion and migration of malignant melanoma cells. NORAD, miR‐205, and EGLN2 mRNA level in MM cells was detected by qRT‐PCR. In situ hybridization (ISH) was performed to detect NORAD expression in MM tissues specimens. Effects of NORAD and miR‐205 on Prolyl hydroxylase 2 (EGLN2) expression was explored by western blot in MM cells line. Dual‐luciferase reporter assay was performed to verify the interaction relationship between NORAD and miR‐205, as well as, miR‐205 and EGLN2. Transwell assay was conducted to explore the effects of NORAD and miR‐205 in vitro. Xenografts in nude mice experiment were used to confirm the role of NORAD and miR‐205 in vivo. In vitro, NORAD knockdown significantly inhibited migration and invasion of malignant melanoma cells and elevated the expression of miR‐205, there was an interaction between miR‐205 and NORAD in the RNA‐induced silencing complex. Upregulation of miR‐205 induced significant inhibition of migratory and invasive ability compared with the scrambled control. However, downregulating NORAD largely reversed this effect. Furthermore, the regulatory effects of miR‐205 on EGLN2 levels and the induction of endoplasmic reticulum stress were reversed by NORAD. In vivo, deletion of miR‐205 induced tumor growth in nude mice. NORAD may play critical roles in tumorigenesis and progression of malignant melanoma by regulating of the miR‐205‐EGLN2 pathway, and may serve as a new therapeutic target.
- Published
- 2019
- Full Text
- View/download PDF
34. Role of serum EBV‐VCA IgG detection in assessing gastric cancer risk and prognosis in Northern Chinese population
- Author
-
Zeyang Wang, Zhi Lv, Hanxi Ding, Qian Xu, Liping Sun, Jingjing Jing, and Yuan Yuan
- Subjects
gastric cancer ,gastric function ,Helicobacter pylori ,prognosis ,risk ,serum EBV ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The study aimed to investigate the role of serum EBV‐VCA IgG in assessing gastric cancer (GC) risk and prognosis. A total of 1790 Northern Chinese participants with pathologically confirmed disease underwent EBV‐VCA IgG serologic testing using enzyme‐linked immunosorbent assay (ELISA), including 821 controls, 410 atrophic gastritis (AG) patients, and 559 GC patients. We found that positive EBV‐VCA IgG was significantly associated with GC and its precursor, conferring a 1.55‐ and 1.36‐fold increased risk of GC and AG, respectively (P = 0.001, 95% CI = 1.21‐1.99; P = 0.011, 95% CI = 1.07‐1.72, respectively). The risk effects were more remarkable in younger, female, and Helicobacter pylori‐negative individuals than in older, male, and H. pylori‐positive individuals. EBV‐VCA IgG‐positive subjects had a lower PGI/II ratio than EBV‐VCA IgG‐negative subjects (median 8.0 vs 8.8, P = 0.001), especially those in the H. pylori‐positive (median 6.1 vs 6.8, P = 0.027) and GC subgroups (median 6.4 vs 7.9, P = 0.020). In the intestinal GC subgroup, the survival of EBV‐VCA IgG‐positive patients was worse than that of EBV‐VCA IgG‐negative patients (P = 0.041, HR = 2.45, 95% CI = 1.04‐5.78). Our study suggests that EBV‐VCA IgG seropositivity has potential in predicting the risk of GC and its precursor as well as the prognosis of histologically classified GC.
- Published
- 2018
- Full Text
- View/download PDF
35. Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
- Author
-
Jingjing Duan, Yu Wang, and Shunchang Jiao
- Subjects
biomarkers ,checkpoint inhibitors ,combination therapy ,immunotherapy ,tumor microenvironment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract A dynamic and mutualistic interaction between tumor cells and tumor microenvironment (TME) promotes the progression and metastasis of solid tumors. Cancer immunotherapy is becoming a major treatment paradigm for a variety of cancers. Although immunotherapy, especially the use of immune checkpoint inhibitors, has achieved clinical success, only a minority of patients exhibits durable responses. Clinical studies directed at identifying appropriate biomarkers and immune profiles that can be used to predict immunotherapy responses are presently being conducted. Combining treatment strategies tailored to cancer‐immune interactions are designed to increase the rate of durable clinical response in patients. It is essential to establish a reasonable tumor classification strategy according to TME to improve cancer immunotherapy. In the current review, a modified classification of TME is proposed, and optimization of TME classification is needed through detailed and integrated molecular characterization of large patient cohorts in the future.
- Published
- 2018
- Full Text
- View/download PDF
36. <scp>ABO</scp> blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women
- Author
-
Chao Wang, Jingjing Zhou, Lili Wang, Tongyu Xing, Hongji Dai, Yao Zhou, Lisha Qi, Yanrui Zhao, Caiyun Huang, Ding Li, Haixin Li, Mulin Jun Li, Ben Liu, Hong Zheng, Kexin Chen, and Lian Li
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging - Abstract
ABO blood groups has been associated with risk of several cancers; however, the results for an association with ovarian cancer are inconsistent and little is known about the expression of histo-blood group (ABH) antigens and ABO gene in ovarian tumor tissues.To assess the impact of genotype-derived ABO blood types on the risk of EOC, we conducted a case-control study in 1,870 EOC and 4,829 controls. Expression of A and B antigen in 70 pairs of ovarian tumor tissues and adjacent normal tissues were detected by immunohistochemistry. Gene expression and DNA methylation profiling was conducted in ovarian tumor tissues.We identified that blood group A was associated with increased risk for EOC compared to blood group O (OR = 1.18, 95% CI = 1.03-1.36, p = 0.019). Increased frequency of aberrant expression of histo-blood group antigens was observed in patients with blood group A (76.5%) compared to patients with blood group O (21.1%) and B (5.0%) by immunohistochemistry (p 0.001). ABO gene expression was down-regulated in ovarian tumor tissues compared with paired adjacent normal tissues (p = 0.027). In addition, ABO gene expression was positively correlated with NFYB (r = 0.38, p 0.001) and inversely correlated with DNA methylation level of four CpG sites on ABO gene (cg11879188, r = - 0.3, p = 0.002; cg22535403, r = - 0.30, p = 0.002; cg13506600, r = - 0.22, p = 0.025; cg07241568, r = - 0.21, p = 0.049) in ovarian tumor tissues.We identified blood group A was associated with increased EOC risk in Chinese women and provided the clues of the possible molecular mechanisms of blood group A related to ovarian cancer risk.
- Published
- 2022
37. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study
- Author
-
Junjie Hang, Lixia Wu, Lina Zhu, Zhiqiang Sun, Ge Wang, Jingjing Pan, Suhua Zheng, Kequn Xu, Jiadi Du, and Hua Jiang
- Subjects
metastatic pancreatic cancer ,open clinical trial ,overall survival ,prognostic nomogram ,real‐world study ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract It is necessary to develop prognostic tools of metastatic pancreatic cancer (MPC) for optimizing therapeutic strategies. Thus, we tried to develop and validate a prognostic nomogram of MPC. Data from 3 clinical trials (NCT00844649, NCT01124786, and NCT00574275) and 133 Chinese MPC patients were used for analysis. The former 2 trials were taken as the training cohort while NCT00574275 was used as the validation cohort. In addition, 133 MPC patients treated in China were taken as the testing cohort. Cox regression model was used to investigate prognostic factors in the training cohort. With these factors, we established a nomogram and verified it by Harrell's concordance index (C‐index) and calibration plots. Furthermore, the nomogram was externally validated in the validation cohort and testing cohort. In the training cohort (n = 445), performance status, liver metastasis, Carbohydrate antigen 19‐9 (CA19‐9) log‐value, absolute neutrophil count (ANC), and albumin were independent prognostic factors for overall survival (OS). A nomogram was established with these factors to predict OS and survival probabilities. The nomogram showed an acceptable discrimination ability (C‐index: .683) and good calibration, and was further externally validated in the validation cohort (n = 273, C‐index: .699) and testing cohort (n = 133, C‐index: .653).The nomogram total points (NTP) had the potential to stratify patients into 3‐risk groups with median OS of 11.7, 7.0 and 3.7 months (P
- Published
- 2018
- Full Text
- View/download PDF
38. Serum exosomal microRNAs combined with alpha‐fetoprotein as diagnostic markers of hepatocellular carcinoma
- Author
-
Yurong Wang, Chunyan Zhang, Pengjun Zhang, Guanghong Guo, Tao Jiang, Xiumei Zhao, Jingjing Jiang, Xueliang Huang, Hongli Tong, and Yaping Tian
- Subjects
Alpha‐fetoprotein ,biomarker ,exosomes ,hepatocellular carcinoma ,microRNA ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Exosomal microRNAs have recently been studied as the potential diagnostic marker for various malignancies, including hepatocellular carcinoma (HCC). The aim of this study was to investigate serum exosomal microRNA profiles as HCC diagnostic marker. Transmission electron microscopy and Western blot were used to identify serum exosomes. Deep sequencing was performed to screen differentially expressed microRNAs between HCC (n = 5) and liver cirrhosis (LC, n = 5) groups. Three upregulated and two downregulated microRNAs were selected for qPCR analysis. The levels of selected microRNAs were normalized to Caenorhabditis elegans miR‐39 microRNA mimics. Serum exosomal level of miR‐122, miR‐148a, and miR‐1246 was further analyzed and significantly higher in HCC than LC and normal control (NC) groups (P 0.05). The receiver operating characteristic curve was used to evaluate the diagnostic performance of candidate microRNAs. Area under the curve (AUC) of miR‐148a was 0.891 [95% confidence interval (CI), 0.809–0.947] in discriminating HCC from LC, remarkably higher than alpha‐fetoprotein (AFP) (AUC: 0.712, 95% CI: 0.607–0.803). Binary logistic regression was adopted to establish the diagnostic model for discriminating HCC from LC. And the combination of miR‐122, miR‐148a, and AFP increased the AUC to 0.931 (95% CI, 0.857–0.973), which can also be applied for distinguishing early HCC from LC. miR‐122 was the best for differentiating HCC from NC (AUC: 0.990, 95% CI, 0.945–1.000). These data suggest that serum exosomal microRNAs signature or their combination with traditional biomarker may be used as a suitable peripheral screening tool for HCC.
- Published
- 2018
- Full Text
- View/download PDF
39. It is not the time to abandon intraoperative frozen section in endometrioid adenocarcinoma: A large‐scale, multi‐center, and retrospective study
- Author
-
Yang, Xiaohang, primary, Yin, Jingjing, additional, Fu, Yu, additional, Shen, Yuanming, additional, Zhang, Chuyao, additional, Yao, Shuzhong, additional, Xu, Congjian, additional, Xia, Min, additional, Lou, Ge, additional, Liu, Jihong, additional, Lin, Bei, additional, Wang, Jianliu, additional, Zhao, Weidong, additional, Zhang, Jieqing, additional, Cheng, Wenjun, additional, Guo, Hongyan, additional, Guo, Ruixia, additional, Xue, Fengxia, additional, Wang, Xipeng, additional, Han, Lili, additional, Li, Xiaomao, additional, Zhang, Ping, additional, Zhao, Jianguo, additional, Li, Wenting, additional, Dou, Yingyu, additional, Wang, Zizhuo, additional, Liu, Jingbo, additional, Li, Kezhen, additional, Chen, Gang, additional, Sun, Chaoyang, additional, Wang, Beibei, additional, and Yang, Xingsheng, additional
- Published
- 2023
- Full Text
- View/download PDF
40. ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women
- Author
-
Wang, Chao, primary, Zhou, Jingjing, additional, Wang, Lili, additional, Xing, Tongyu, additional, Dai, Hongji, additional, Zhou, Yao, additional, Qi, Lisha, additional, Zhao, Yanrui, additional, Huang, Caiyun, additional, Li, Ding, additional, Li, Haixin, additional, Li, Mulin Jun, additional, Liu, Ben, additional, Zheng, Hong, additional, Chen, Kexin, additional, and Li, Lian, additional
- Published
- 2022
- Full Text
- View/download PDF
41. Identification of a novel six‐gene signature with potential prognostic and therapeutic value in cervical cancer
- Author
-
Junjun Qiu, Xinyu Qu, Chenyan Guo, Jingjing Guo, Zhiwen Shi, and Keqin Hua
- Subjects
Cancer Research ,Microarray ,Bioinformatics ,cervical cancer ,Immune checkpoint inhibitors ,Uterine Cervical Neoplasms ,Biology ,gene signature ,Immune system ,Tumor Microenvironment ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Gene ,Research Articles ,RC254-282 ,Cervical cancer ,tumour immune microenvironment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Middle Aged ,Gene signature ,medicine.disease ,Gene Expression Regulation, Neoplastic ,Oncology ,Cancer research ,Biomarker (medicine) ,Female ,Identification (biology) ,prognosis ,Research Article - Abstract
Introduction Cervical cancer has high mortality, high recurrence and poor prognosis. Although prognostic biomarkers such as clinicopathological features have been proposed, their accuracy and precision are far from satisfactory. Therefore, novel biomarkers are urgently needed for disease surveillance, prognosis prediction and treatment selection. Materials Differentially expressed genes (DEGs) between cervical cancer and normal tissues from three microarray datasets extracted from the Gene Expression Omnibus platform were identified and screened. Based on these DEGs, a six‐gene prognostic signature was constructed using cervical squamous cell carcinoma and endocervical adenocarcinoma data from The Cancer Genome Atlas. Next, the molecular functions and related pathways of the six genes were investigated through gene set enrichment analysis and co‐expression analysis. Additionally, immunophenoscore analysis and the QuartataWeb Server were employed to explore the therapeutic value of the six‐gene signature. Results We discovered 178 overlapping DEGs in three microarray datasets and established a six‐gene (APOC1, GLTP, ISG20, SPP1, SLC24A3 and UPP1) prognostic signature with stable and excellent performance in predicting overall survival in different subgroups. Intriguingly, the six‐gene signature was closely associated with the immune response and tumour immune microenvironment. The six‐gene signature might be used for predicting response to immune checkpoint inhibitors (ICIs) and the six genes may serve as new drug targets for cervical cancer. Conclusion Our study established a novel six‐gene (APOC1, GLTP, ISG20, SPP1, SLC24A3 and UPP1) signature that was closely associated with the immune response and tumour immune microenvironment. The six‐gene signature was indicative of aggressive features of cervical cancer and therefore might serve as a promising biomarker for predicting not only overall survival but also ICI treatment effectiveness. Moreover, three genes (UPP1, ISG20 and GLTP) within the six‐gene signature have the potential to become novel drug targets., Our study established a novel six‐gene (APOC1, GLTP, ISG20, SPP1, SLC24A3 and UPP1) signature that was closely associated with the immune response and the tumour immune microenvironment. The six‐gene signature was indicative of aggressive features of cervical cancer and therefore might serve as a promising biomarker for predicting not only overall survival but also immune checkpoint inhibitor treatment effectiveness. Moreover, three genes (UPP1, ISG20 and GLTP) within the six‐gene signature have the potential to become novel drug targets.
- Published
- 2021
42. ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation
- Author
-
Hongyan Zhu, Peng Duan, Chuang Zhang, Jian Long, Jingjing Lin, and Jianjun Tang
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Cancer Research ,Cell Survival ,MAP Kinase Signaling System ,medicine.medical_treatment ,Antineoplastic Agents ,5‐HETE ,medicine.disease_cause ,chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Hydroxyeicosatetraenoic Acids ,Medicine ,Humans ,Hydroxyurea ,Radiology, Nuclear Medicine and imaging ,Lipoxygenase Inhibitors ,Phosphorylation ,Research Articles ,RC254-282 ,Cancer Biology ,Cell Proliferation ,Chemotherapy ,Analysis of Variance ,Arachidonate 5-Lipoxygenase ,business.industry ,gastric cancer ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Zileuton ,medicine.disease ,Alox5 ,Up-Regulation ,zileuton ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Disease Progression ,Signal transduction ,business ,Carcinogenesis ,MEK/ERK ,medicine.drug ,Research Article - Abstract
Background Recent studies highlight the regulatory role of arachidonate lipoxygenase5 (Alox5) and its metabolite 5‐hydroxyeicosatetraenoic acid (5‐HETE) in cancer tumorigenesis and progression. In this study, we analyzed the expression, biological function and the downstream signaling of Alox5 in gastric cancer. Methods Alox5 protein levels were measured using IHC and ELISA. Growth, migration and survival assays were performed. Phosphorylation of molecules involved in growth and survival signaling were analyzed by WB. Analysis of variance and t‐test were used for statistic analysis. Results Alox5 and 5‐HETE levels were upregulated in gastric cancer patients. ALOX5 overexpression or 5‐HETE addition activates gastric cancer cells and reduces chemotherapy’s efficacy. In contrast, ALOX5 inhibition via genetic and pharmacological approaches suppresses gastric cancer cells and enhances chemotherapy’s efficacy. In addition, Alox5 inhibition led to suppression of ERK‐mediated signaling pathways whereas ALOX5‐5‐HETE activates ERK‐mediated signaling in gastric cancer cells. Conclusions Our work demonstrates the critical role of ALOX5‐5‐HETE in gastric cancer and provides pre‐clinical evidence to initialize clinical trial using zileuton in combination with chemotherapy for treating gastric cancer., Our work demonstrates that the ALOX5‐5‐HETE axis promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation and provides pre‐clinical evidence to initialize clinical trials using zileuton in combination with chemotherapy for the treatment of gastric cancer.
- Published
- 2021
43. Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
- Author
-
Depei Wu, Xiaolan Shi, Guanghua Chen, Song Jin, Lingzhi Yan, Nan Xu, Chengcheng Fu, Xiaming Zhu, Ming-Qing Zhu, Su Qu, Ying Yao, Huirong Chang, Jin Zhou, Weiqin Yao, Jingjing Shang, Liqing Kang, and Lei Yu
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,efficacy ,Immunotherapy, Adoptive ,0302 clinical medicine ,Multiple myeloma ,Original Research ,Receptors, Chimeric Antigen ,biology ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Survival Rate ,multiple myeloma ,Tolerability ,030220 oncology & carcinogenesis ,Toxicity ,relapsed and/or refractory ,Female ,Cart ,safety ,medicine.medical_specialty ,Antigens, CD19 ,lcsh:RC254-282 ,CD19 ,03 medical and health sciences ,Antigen ,Refractory ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,B-Cell Maturation Antigen ,Aged ,Salvage Therapy ,business.industry ,Clinical Cancer Research ,chimeric antigen receptor T (CAR T) cell ,medicine.disease ,Chimeric antigen receptor ,030104 developmental biology ,Drug Resistance, Neoplasm ,biology.protein ,dose‐escalation ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell maturation antigen (BCMA)‐CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patients, among whom 7 received autologous infusion and 3 received allogeneic infusion. The median follow‐up time was 20 months. The most common grade 3/4 treatment‐emergent toxicities were hematological toxicities. Cytokine‐release syndrome (CRS) adverse reactions were grade 1/2 in 9 out of 10 subjects. No dose‐limited toxicity (DLT) was observed for BCMA‐CAR‐positive T cells ≤5 × 107/kg), while two patients with dose‐levels of 5–6.5 × 107/kg experienced DLTs. The overall response rate was 90% (five partial responses and four stringent complete responses). Three out of four patients with stringent complete responses to autologous CART had progression‐free survival for over 2 years. The three patients with allogeneic CART experienced disease progression within 2 months. These results evidence the sequential infusion's preliminarily tolerability and efficacy in RRMM, and present a simple and safe design applicable for the establishment of multiple CART therapy., We conducted a pilot study to assess the feasibility of the sequential infusion of CD19 and B‐cell maturation antigen (BCMA)‐specific chimeric antigen receptor T‐cell (CART) for relapsed and/or refractory multiple myeloma treatment with a similar 3 + 3 dose escalation design. Translational Significance: The favorable and persistent responses against RRMM were observed in those patients with a combined infusion of autologous CD19‐CART and BCMA‐CART. The emergence of intolerant adverse event (neurotoxicity and sever CRS) was associated with increased dose level of BCMA‐CARTs infusion.
- Published
- 2021
44. The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
- Author
-
Chen, Hanxiao, primary, Huang, Dingzhi, additional, Lin, Gen, additional, Yang, Xue, additional, Zhuo, Minglei, additional, Chi, Yujia, additional, Zhai, Xiaoyu, additional, Jia, Bo, additional, Wang, Jingjing, additional, Wang, Yuyan, additional, Li, Jianjie, additional, An, Tongtong, additional, Wu, Meina, additional, Wang, Ziping, additional, and Zhao, Jun, additional
- Published
- 2022
- Full Text
- View/download PDF
45. Distribution and susceptibility of ERCC1/XPF gene polymorphisms in Han and Uygur women with breast cancer in Xinjiang, China
- Author
-
Jingjing Fan, Tong Sha, Yi Zheng, Jing Ma, Zhen Zhai, Yuyao Zhu, Na Li, Linghui Zhou, Hongtao Li, Binlin Ma, and Zhijun Dai
- Subjects
gene polymorphisms ,0301 basic medicine ,China ,Cancer Research ,medicine.medical_specialty ,Uygur ,Genotype ,Breast Neoplasms ,Single-nucleotide polymorphism ,Polymorphism, Single Nucleotide ,Gastroenterology ,susceptibility ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,Asian People ,Risk Factors ,Internal medicine ,Genetic model ,Ethnicity ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Gene ,Original Research ,Cancer Biology ,business.industry ,Han ,Middle Aged ,Endonucleases ,medicine.disease ,DNA-Binding Proteins ,030104 developmental biology ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Female ,ERCC1 ,business - Abstract
This study aimed to explore the roles of ERCC1/XPF gene polymorphisms in the occurrence of breast cancer in the Uygur and Han ethnic groups in Xinjiang, China. Single nucleotide polymorphisms (SNPs) were detected by TaqMan real‐time PCR. The rs11615 G>A and rs2276466 C>G variant frequencies were higher in Uygur patients with breast cancer than in Han patients, while the frequency of rs2298881 C>A was higher in Han patients. We found that rs2298881 C>A (CA vs. CC: OR = 0.35, 95% CI = 0.20‐0.60; AA vs. CC: OR = 0.13, 95% CI = 0.04‐0.34; CA + AA vs. CC: OR = 0.33, 95% CI = 0.18‐0.51; AA vs. CA + CC: OR = 0.24, 95% CI = 0.08‐0.62; CA vs. AA + CC: OR = 0.49, 95% CI = 0.29‐0.82) was associated with a reduced breast cancer risk and rs3212986 C>A (AA vs. CC: OR = 4.80, 95% CI = 1.79‐15.29,; CA+AA vs. CC: OR = 1.71, 95% CI = 1.06‐2.77; AA vs. CA+CC: OR = 4.12, 95% CI =1.58‐12.89) and rs11615 G > A (AA vs. GG: OR = 3.49, 95% CI =1.54‐8.55; GA + AA vs. GG: OR = 1.98, 95% CI = 1.21‐3.27; AA vs. GA+GG: OR = 2.87, 95% CI = 1.30‐6.85) were associated with an elevated breast cancer risk among Uygur individuals. In addition, Uygur patients with breast cancer with 2‐3 combined risk genotypes of ERCC1 had a higher risk than patients with 0‐1 risk genotypes (OR = 2.91; 95% CI = 1.54‐5.71, p = 0.001). However, we failed to detect a statistically significant association between ERCC1/XPF polymorphisms and breast cancer risk in five genetic models among Han individuals. Our results showed that ERCC1/XPF gene polymorphisms predispose Uygur individuals to breast cancer; this finding should be verified by further large‐scale analyses., Distribution of ERCC1/XPF gene polymorphisms in Han and Uygur women with breast cancer was different. ERCC1/XPF gene polymorphisms predispose Uygur individuals to breast cancer.
- Published
- 2020
46. Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
- Author
-
Yuanyuan Ma, Xuguang Song, Feng Zhu, Hai Cheng, Haiying Sun, Depeng Li, Jiang Cao, Meixue Yao, Jingjing Yang, Kailin Xu, Ming Shi, Weidong Li, Cai Sun, Hui Liu, Jun Jiao, Mei Wu, Yuanyuan Qin, Linyan Xu, Kemeng Sun, Xiang Gao, Ying Wang, Junnian Zheng, Zhenyu Li, Bing Zhang, Lingyu Zeng, Zhiling Yan, Dongmei Yan, Tingting Sang, and Wei Sang
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Time Factors ,Transplantation Conditioning ,T-Lymphocytes ,Immunotherapy, Adoptive ,Gastroenterology ,CAR‐T ,0302 clinical medicine ,Recurrence ,immune system diseases ,hemic and lymphatic diseases ,Refractory Diffuse Large B-Cell Lymphoma ,Original Research ,CD20 ,B-Lymphocytes ,Receptors, Chimeric Antigen ,biology ,CD19 ,Anemia ,clinical trial ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Progression-Free Survival ,Fludarabine ,Cytokine release syndrome ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Toxicity ,Female ,Lymphoma, Large B-Cell, Diffuse ,Cytokine Release Syndrome ,Glycolysis ,Vidarabine ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Cyclophosphamide ,Antigens, CD19 ,CD4-CD8 Ratio ,Antineoplastic Agents ,lcsh:RC254-282 ,Young Adult ,03 medical and health sciences ,Antigen ,Internal medicine ,Confidence Intervals ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Ifosfamide ,Aged ,business.industry ,Clinical Cancer Research ,Antigens, CD20 ,medicine.disease ,Thrombocytopenia ,030104 developmental biology ,DLBCL ,biology.protein ,business ,Diffuse large B-cell lymphoma - Abstract
Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Methods Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti‐CD19 and anti‐CD20 CAR‐T cells. Treatment response, toxicity, and persistence were monitored continuously. Results Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%‐94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%‐74.3%) had a complete response (CR). Peak levels of anti‐CD19 and anti‐CD20 CAR cells were associated with response (P = .007 and .002). Grade 3‐4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression‐free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. Conclusions Coadministration of anti‐CD19 and CD20 CAR‐T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178., In this study, we confirmed that combination of anti‐CD19 and anti‐CD20 CAR‐T cells therapy strategy was efficient (81% ORR and 52.4% CR respectively) for R/R DLBCL, and that the toxicities was transient and manageable. To our knowledge, this is the first report that combination of anti‐CD19 and anti‐CD20 double‐target CAR‐T cell therapy for R/R DLBCL, and our data demonstrated the feasibility of combination of anti‐CD19 and anti‐CD20 CAR‐T cells therapy for R/R DLBCL.
- Published
- 2020
47. Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia
- Author
-
Ting Yang, Minhui Lin, Donghui Gan, Zhengjun Wu, Peifang Jiang, Jingjing Wen, Jianda Hu, Jiazheng Li, Yanxin Chen, Yuwen Chen, Yingyu Chen, and Lingyan Wang
- Subjects
signaling pathway ,0301 basic medicine ,Cancer Research ,Candidate gene ,Cell ,acute lymphoblastic leukemia ,MYC ,Computational biology ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,glucocorticoid resistance ,Biomarkers, Tumor ,medicine ,Humans ,Gene Regulatory Networks ,Radiology, Nuclear Medicine and imaging ,Protein Interaction Maps ,KEGG ,Glucocorticoids ,Gene ,Original Research ,Cancer Biology ,Mechanism (biology) ,Gene Expression Profiling ,Computational Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Chemotherapy regimen ,bioinformatic analysis ,In vitro ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Signal transduction ,Transcriptome - Abstract
Glucocorticoids (GC) are the foundation of the chemotherapy regimen in acute lymphoblastic leukemia (ALL). However, resistance to GC is observed more frequently than resistance to other chemotherapy agents in patients with ALL relapse. Moreover, the mechanism underlying the development of GC resistance in ALL has not yet been fully uncovered. In this study, we used bioinformatic analysis methods to integrate the candidate genes and pathways participating in GC resistance in ALL and subsequently verified the bioinformatics findings with in vitro cell experiments. Ninety‐nine significant common differentially expressed genes (DEGs) associated with GC resistance were determined by integrating two gene profile datasets, including GC‐sensitive and ‐resistant samples. Using Kyoto Encyclopedia of Genes and Genomes (KEGG) and REACTOME pathways analysis, the signaling pathways in which DEGs were significantly enriched were clustered. The GC resistance‐related biologically functional interactions were visualized as DEG‐associated Protein–Protein Interaction (PPI) network complexes, with 98 nodes and 127 edges. MYC, a node which displayed the highest connectivity in all edges, was highlighted as the core gene in the PPI network. Increased C‐MYC expression was observed in adriamycin‐resistant BALL‐1/ADR cells, which we demonstrated was also resistant to dexamethasone. These results outlined a panorama in which the solitary and scattered experimental results were integrated and expanded. The potential promising target of the candidate pathways and genes involved in GC resistance of ALL was concomitantly revealed., These results outlined a panorama in which the solitary and scattered experimental results were integrated and extended. The potential promising target of the candidate pathways and genes in GC resistant acute lymphoblastic leukemia was concomitantly revealed.
- Published
- 2020
48. MicroRNA‐124: An emerging therapeutic target in cancer
- Author
-
Xiaorong Guo, Maomao Zhang, Jingjing Ji, Sheng Tai, Wenjia Zhou, Ge Lou, Mian Guo, Shan Yu, Chao Li, Junjie Zhao, Xu Wang, and Xinqi Jia
- Subjects
0301 basic medicine ,Cancer Research ,Programmed cell death ,Review ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,microRNA ,medicine ,Humans ,cancer ,oncotherapy target ,Radiology, Nuclear Medicine and imaging ,Gene ,Cell Proliferation ,Cancer Biology ,Messenger RNA ,Gene targets ,Cancer ,Cell Differentiation ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,miR‐124 ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,miRNAs ,Cancer research ,Human cancer - Abstract
MicroRNAs (miRNAs) are noncoding single‐stranded RNAs, approximately 20‐24 nucleotides in length, known as powerful posttranscriptional regulators. miRNAs play important regulatory roles in cellular processes by changing messenger RNA expression and are widely involved in human diseases, including tumors. It has been reported in the literature that miRNAs have a precise role in cell proliferation, programmed cell death, differentiation, and expression of coding genes. MicroRNA‐124 (miR‐124) has reduced exparession in various human neoplasms and is believed to be related to the occurrence, development, and prognosis of malignant tumors. In our review, we focus on the specific molecular functions of miR‐124 and the downstream gene targets in major cancers, which provide preclinical evidence for the treatment of human cancer. Although some obstacles exist, miR‐124 is still attracting intensive research focus as a promising and effective anticancer weapon., miRNA‐124 is closely related to the cancer development and progression, and decreased in many cancer types. Increasing miRNA‐124 levels, inhibiting cancer cell proliferation, and affecting clinical outcome. miRNA‐124 has the potential to be a target for cancer treatment.
- Published
- 2019
49. Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway
- Author
-
Fan Wang, Chuanyong Guo, Tong Liu, Jie Ji, Weiqi Dai, Kan Chen, Jie Zhang, Yuqing Mao, Xiaoming Fan, Qiang Yu, Sainan Li, Jianye Wu, Jiao Feng, Jiaojiao Chen, Jingjing Li, Liwei Wu, and Yuting Zhou
- Subjects
0301 basic medicine ,STAT3 Transcription Factor ,JAK2/STAT3 pathway ,Cancer Research ,autophagy ,Carcinoma, Hepatocellular ,Cell Survival ,H&E stain ,Mice, Nude ,Antineoplastic Agents ,lcsh:RC254-282 ,Stat3 Signaling Pathway ,Metastasis ,quercetin ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Cell Movement ,Medicine ,Animals ,metastasis ,Radiology, Nuclear Medicine and imaging ,heterocyclic compounds ,Original Research ,Cancer Biology ,Cell Proliferation ,business.industry ,Liver Neoplasms ,apoptosis ,Cancer ,hepatocellular carcinoma ,Janus Kinase 2 ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Xenograft Model Antitumor Assays ,030104 developmental biology ,Oncology ,chemistry ,Mechanism of action ,Apoptosis ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Cancer research ,medicine.symptom ,business ,Quercetin ,Signal Transduction - Abstract
Objective Hepatocellular carcinima is one of the most common tumors in clinic and also one of the leading causes of death from cancer worldwide. Quercetin shows significant effects on blocking the development of various cancers. Methods We used the human hepatocellular carcinoma LM3 and nude mice tumor model to assess the effects of quercetin in hepatocellular carcinoma and clarify its mechanism of action. We collected LM3 cell line treated with different doses of quercetin at different time periods and determined the vital indexes. The liver tissues of mice were collected and used for western boltting (WB), Hematoxylin and Eosin (H&E) and TUNEL staining. Results Results indicated that quercetin suppressed the Hepatocellular carcinoma (HCC) growth both in vivo and in vitro. Quercetin could disturb LM3 cells proliferation and cell cycle distribution, thus inducing apoptosis. At the same time, quercetin inhibited LM3 cells migration and invasion and promoted HCC autophagy. These effects at least partly depended on the down‐regulation of the activation of JAK2 and STAT3 by quercetin. Conclusion Quercetin inhibited hepatocellular carcinoma progression by modulating cell apoptosis, migration, invasion, and autophagy; and its effects were at least partly related with the JAK2/STAT3 signaling pathway.
- Published
- 2019
50. Identification of a novel six‐gene signature with potential prognostic and therapeutic value in cervical cancer
- Author
-
Qu, Xinyu, primary, Shi, Zhiwen, additional, Guo, Jingjing, additional, Guo, Chenyan, additional, Qiu, Junjun, additional, and Hua, Keqin, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.